Evidence map›Paper›PMID 34258473›Full record

ArticleAdvances in radiation oncology

Dosimetric Impact of Acuros XB Dose-to-Water and Dose-to-Medium Reporting Modes on Lung Stereotactic Body Radiation Therapy and Its Dependency on Structure Composition.

Carles Muñoz-Montplet, Rafael Fuentes-Raspall, Diego Jurado-Bruggeman, Sebastià Agramunt-Chaler, Albert Onsès-Segarra, Maria Buxó

Abstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Lung SBRT: Dose gradient optimization based on target size.Medical dosimetry : official journal of the American Association of Medical Dosimetrists
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carles Muñoz-MontpletMedical Physics and Radiation Protection Department, Institut Català d'Oncologia, Avda. França s/n, 17007 Girona, Spain.
Rafael Fuentes-RaspallDepartment of Medical Sciences, University of Girona, C/Emili Grahit 77, 17003 Girona, Spain.
Diego Jurado-BruggemanMedical Physics and Radiation Protection Department, Institut Català d'Oncologia, Avda. França s/n, 17007 Girona, Spain.
Sebastià Agramunt-ChalerMedical Physics and Radiation Protection Department, Institut Català d'Oncologia, Avda. França s/n, 17007 Girona, Spain.
Albert Onsès-SegarraMedical Physics and Radiation Protection Department, Institut Català d'Oncologia, Avda. França s/n, 17007 Girona, Spain.
Maria BuxóGirona Biomedical Research Institute (IDIBGI), Parc Hospitalari Martí i Julià, Edifici M2, 17190, Salt, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur purpose was to assess the dosimetric effect of switching from the analytical anisotropic algorithm (AAA) to Acuros XB (AXB), with dose-to-medium (Dm) and dose-to-water (Dw) reporting modes, in lung stereotactic body radiation therapy patients and determine whether planning-target-volume (PTV) dose prescriptions and organ-at-risk constraints should be modified under these circumstances. METHODS AND MATERIALS: We included 54 lung stereotactic body radiation therapy patients. We delineated the PTV, the ipsilateral lung, the contralateral lung, the heart, the spinal cord, the esophagus, the trachea, proximal bronchi, the ribs, and the great vessels. We performed dose calculations with AAA and AXB, then compared clinically relevant dose-volume parameters. Paired

resultsThe largest difference between the algorithms was 4%. Mean dose differences between AXB Dm and AXB Dw depended on the average composition of the volumes. Compared with AXB, AAA underestimated all PTV dose-volume parameters (-0.7 Gy to -0.1 Gy) except for gradient index, which was significantly higher (4%). It also underestimated V

conclusionsDifferences between AXB and AAA are below the threshold of clinical detectability (5%) for most patients. For a small subgroup, the difference in maximum doses to the ribs between AXB Dw and AXB Dm may be clinically significant. The differences in dose volume parameters between AXB Dw and AXB Dm can be predicted with reference to structure composition.

Identifiers

PMID34258473
PMCPMC8256186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.